Format
Sort by
Items per page

Send to

Choose Destination

Best matches for FILGRASTIM/TU:

Tbo-Filgrastim: A Review in Neutropenic Conditions. Blair HA et al. BioDrugs. (2016)

Zarxio--a filgrastim biosimilar. et al. Med Lett Drugs Ther. (2016)

Conversion from Filgrastim to Tbo-filgrastim: Experience of a Large Health Care System. Agboola F et al. J Manag Care Spec Pharm. (2017)

Search results

Items: 1 to 20 of 176

1.

Uptake of the Biologic Filgrastim and Its Biosimilar Product Among the Medicare Population.

Kozlowski S, Birger N, Brereton S, McKean SJ, Wernecke M, Christl L, Kelman JA.

JAMA. 2018 Sep 4;320(9):929-931. doi: 10.1001/jama.2018.9014. No abstract available.

PMID:
30193265
2.

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers.

Choi C, Yoo BW, Kim CO, Hong T, Jin BH, Seo KS, Jang JY, Park MS.

Drug Des Devel Ther. 2018 Aug 1;12:2381-2387. doi: 10.2147/DDDT.S158277. eCollection 2018.

3.

Immunogenicity assessment of tbo-filgrastim in cancer patients receiving chemotherapy.

Zou L, Buchner A, Field JA, Barash S, Liu PM.

Bioanalysis. 2018 Aug 1;10(15):1221-1228. doi: 10.4155/bio-2018-0071. Epub 2018 Jul 30.

PMID:
30058363
4.

Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors.

Iwasa S, Yamamoto N, Shitara K, Tamura K, Matsubara N, Tajimi M, Lin AB, Asou H, Cai Z, Inoue K, Shibasaki Y, Saito K, Takai H, Doi T.

Cancer Sci. 2018 Oct;109(10):3216-3223. doi: 10.1111/cas.13750.

5.

Efficacy and Safety of Bi-weekly Pegfilgrastim for Dose-dense Chemotherapy-induced Neutropenia in Breast Cancer Patients.

Mori H, Kubo M, Kai M, Kurata K, Yamada M, Nakamura M.

Anticancer Res. 2018 Jul;38(7):4381-4386. doi: 10.21873/anticanres.12740.

PMID:
29970577
6.

Effectiveness and Safety of Pegfilgrastim in BEP Treatment for Patients with Germ Cell Tumor.

Iwamoto H, Izumi K, Natsagdorj A, Makino T, Nohara T, Shigehara K, Kadono Y, Mizokami A.

In Vivo. 2018 Jul-Aug;32(4):899-903. doi: 10.21873/invivo.11326.

7.
8.

Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim.

Grewal S, Ramsey S, Balu S, Carlson JJ.

Expert Rev Pharmacoecon Outcomes Res. 2018 Aug;18(4):447-454. doi: 10.1080/14737167.2018.1476142. Epub 2018 May 18.

PMID:
29757040
9.

A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim.

Waller CF, Tiessen RG, Lawrence TE, Shaw A, Liu MS, Sharma R, Baczkowski M, Kothekar MA, Micales CE, Barve A, Ranganna GM, Pennella EJ.

J Cancer Res Clin Oncol. 2018 Jun;144(6):1087-1095. doi: 10.1007/s00432-018-2643-3. Epub 2018 Apr 18.

PMID:
29671069
10.

Predictive factors in patients eligible for pegfilgrastim prophylaxis focusing on RDI using ordered logistic regression analysis.

Kanbayashi Y, Ishikawa T, Kanazawa M, Nakajima Y, Kawano R, Tabuchi Y, Yoshioka T, Ihara N, Hosokawa T, Takayama K, Shikata K, Taguchi T.

Med Oncol. 2018 Mar 16;35(4):55. doi: 10.1007/s12032-018-1116-5.

PMID:
29549536
11.

Lenograstim 5 µg/kg is not superior to biosimilar filgrastim 10 µg/kg in lymphoma patients undergoing peripheral blood stem cell mobilization after chemotherapy: preliminary results from a prospective randomized study.

Marchesi F, Vacca M, Giannarelli D, Ipsevich F, Pandolfi A, Gumenyuk S, Renzi D, Palombi F, Pisani F, Romano A, Spadea A, Papa E, Canfora M, Pierelli L, Mengarelli A.

Transfusion. 2018 May;58(5):1143-1148. doi: 10.1111/trf.14533. Epub 2018 Feb 15.

PMID:
29446445
12.

Pseudogout Attack after Pegfilgrastim Administration in Anaplastic Large Cell Lymphoma.

Hatayama M, Ikuta K, Ishioh M, Saito T, Toki Y, Yamamoto M, Shindo M, Torimoto Y, Okumura T.

Intern Med. 2018 Jun 15;57(12):1779-1782. doi: 10.2169/internalmedicine.9362-17. Epub 2018 Feb 9.

13.

Clinical safety and efficacy of "filgrastim biosimilar 2" in Japanese patients in a post-marketing surveillance study.

Tamura K, Hashimoto K, Nishikawa K.

J Infect Chemother. 2018 May;24(5):363-369. doi: 10.1016/j.jiac.2017.12.011. Epub 2018 Feb 3.

14.

[Effect of Pegfilgrastim Primary Prophylactic Administration on Relative Dose Intensity(RDI)in Postoperative Adjuvant Chemotherapy(TC Therapy)for Breast Cancer - A Single-Center, Retrospective Study].

Nagashima Y, Chijimatsu H, Furuya K, Kondo J, Maeda Y, Somura H, Takemoto N, Yahara N, Abe T, Hayashi H, Kubo H, Yamamoto S, Nagano H.

Gan To Kagaku Ryoho. 2017 Dec;44(13):2087-2090. Japanese.

PMID:
29361623
15.

The Case | Acute kidney injury in a 78-year-old man with low-grade B-cell lymphoma.

Elabd H, Nayak R, Rashid T, Stokes MB.

Kidney Int. 2018 Jan;93(1):275-276. doi: 10.1016/j.kint.2017.07.001. No abstract available.

PMID:
29291825
16.
17.

[Diffuse large B-cell lymphoma complicated with drug-induced vasculitis during administration of pegfilgrastim].

Ito Y, Noda K, Aiba K, Yano S, Fujii T.

Rinsho Ketsueki. 2017;58(11):2238-2242. doi: 10.11406/rinketsu.58.2238. Review. Japanese.

PMID:
29212975
18.

A Comparison of Brand and Biosimilar Granulocyte-Colony Stimulating Factors for Prophylaxis of Chemotherapy-Induced Febrile Neutropenia.

Douglas AG, Schwab P, Lane D, Kennedy K, Slabaugh SL, Bowe A.

J Manag Care Spec Pharm. 2017 Dec;23(12):1221-1226. doi: 10.18553/jmcp.2017.23.12.1221.

19.

Pharmacovigilance of Biologics in a Multisource Environment.

Sagi S, Cohen HP, Woollett GR.

J Manag Care Spec Pharm. 2017 Dec;23(12):1249-1254. doi: 10.18553/jmcp.2017.23.12.1249.

20.

Application of the FDA Biosimilar Extrapolation Framework to Make Off-Label Determinations.

Li E, Lobaina E.

J Manag Care Spec Pharm. 2017 Dec;23(12):1227-1232. doi: 10.18553/jmcp.2017.23.12.1227.

Supplemental Content

Loading ...
Support Center